scispace - formally typeset
M

Mukesh Pasupuleti

Researcher at Central Drug Research Institute

Publications -  98
Citations -  4177

Mukesh Pasupuleti is an academic researcher from Central Drug Research Institute. The author has contributed to research in topics: Antimicrobial peptides & Antimicrobial. The author has an hindex of 29, co-authored 91 publications receiving 3277 citations. Previous affiliations of Mukesh Pasupuleti include Memorial University of Newfoundland & Council of Scientific and Industrial Research.

Papers
More filters
Journal ArticleDOI

Antimicrobial peptides: key components of the innate immune system

TL;DR: An overview of cationic antimicrobial peptides, origin, structure, functions, and mode of action of AMPs, which are highly expressed and found in humans, as well as a brief discussion about widely abundant, well characterized AMPs in mammals.
Journal ArticleDOI

Strategies for Fermentation Medium Optimization: An In-Depth Review.

TL;DR: An attempt has been made to review the currently used media optimization techniques applied during fermentation process of metabolite production and provide the rationale for the selection of suitable optimization technique for media designing employed during the fermentation process.
Journal ArticleDOI

Evaluation of Strategies for Improving Proteolytic Resistance of Antimicrobial Peptides by Using Variants of EFK17, an Internal Segment of LL-37

TL;DR: Overall, W substitutions constitute an interesting means to reduce the proteolytic susceptibility of EFK17 while also improving antimicrobial performance.
Journal ArticleDOI

Proteolysis of human thrombin generates novel host defense peptides.

TL;DR: These findings provide a novel link between the coagulation system and host-defense peptides, two fundamental biological systems activated in response to injury and microbial invasion.
Journal ArticleDOI

Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli.

TL;DR: Data indicate that this new method represents a cost-effective means to enable commercial enterprises to produce cationic antimicrobial host defense peptides in large-scale under Good Laboratory Manufacturing Practice (GMP) conditions for therapeutic application in humans.